Selective arterial embolization of symptomatic and asymptomatic renal angiomyolipomas: a retrospective study of safety, outcomes and tumor size reduction.

Date publication

février 2017

Journal

Quantitative imaging in medicine and surgery

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie , Pr CORMIER Luc , Pr LOFFROY Romaric

Tous les auteurs :
Bardin F, Chevallier O, Bertaut A, Delorme E, Moulin M, Pottecher P, Di Marco L, Gehin S, Mourey E, Cormier L, Mousson C, Midulla M, Loffroy R

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28275556

Résumé

Angiomyolipoma (AML) is the most common renal benign tumor. Treatment should be considered for symptomatic patients or for those at risk for complications, especially retroperitoneal bleeding which is correlated to tumor size, grade of the angiogenic component and to the presence of tuberous sclerosis complex (TSC). This study reports our single-center experience with the use of selective arterial embolization (SAE) in the management of symptomatic and asymptomatic renal AMLs.

Mots clés

Renal tumor, angiomyolipoma (AML), arterial embolization, bleeding patient, outcomes, therapeutic response

Référence

Quant Imaging Med Surg. 2017 Feb;7(1):8-23